Document Detail


Oxytocin administration attenuates atherosclerosis and inflammation in Watanabe Heritable Hyperlipidemic rabbits.
MedLine Citation:
PMID:  22998949     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxytocin (OT) is a neurohypophyseal peptide traditionally associated with female reproductive functioning, and more recently with prosocial behavior. OT and its receptor are also expressed in the heart and vascular tissue and play a role in cardiovascular homeostasis. In vitro, it has been demonstrated that OT decreases NADPH-dependent superoxide production and pro-inflammatory cytokine release from vascular endothelial cells and macrophages, suggesting that OT may attenuate pathophysiological processes involved with atherosclerotic lesion formation. The present study sought to determine the effect of chronic exogenous OT administration on inflammation and atherosclerosis in an animal model of dyslipidemia and atherosclerosis, the Watanabe Heritable Hyperlipidemic (WHHL) rabbit. Twenty-two, 3-month-old WHHLs were surgically implanted with osmotic mini-pumps containing OT (n=11) or vehicle (n=11), and then were individually housed for the entire study. Blood and 24-h urine samples were taken at baseline and after 8 (midpoint) and 16 (endpoint) weeks of treatment. At endpoint, the aortas and visceral fat samples were dissected and stored for analyses. There were no group differences in body weight, serum lipids, plasma/urinary measures of oxidative stress, plasma cortisol or urinary catecholamines over the 16-week treatment. OT-treated animals exhibited significantly lower plasma C-reactive protein levels at midpoint and endpoint and developed significantly less atherosclerosis in the thoracic aorta relative to vehicle control animals at endpoint (p<0.05). Cytokine gene expression from visceral adipose tissue samples suggested that there was a decrease in adipose tissue inflammation in the OT-treated group compared to the vehicle control group, however these differences were not statistically significant. These results suggest that chronic peripheral OT administration can inhibit inflammation and atherosclerotic lesion development.
Authors:
Angela Szeto; Maria A Rossetti; Armando J Mendez; Crystal M Noller; Edward E Herderick; Julie A Gonzales; Neil Schneiderman; Philip M McCabe
Related Documents :
23572709 - Effect of incorporation of chicken blood plasma on physico-chemical properties of cakes.
23201819 - Plasma concentrations of cyclic volatile methylsiloxanes (cvms) in pregnant and postmen...
24036419 - The effects of stress hormones on growth of selected periodontitis related bacteria.
24600079 - Serum endostatin concentrations are higher in men with symptoms of intermittent claudic...
24505199 - Serum concentration of vascular endothelial growth factor after bilateral intravitreal ...
24082319 - Effects of a chinese medicinal plant radix astragali on the ovariectomized female rats.
7527229 - Serum and urine inorganic fluoride levels following prolonged low-dose sevoflurane anes...
9835369 - Reproductive seasonality and maturation throughout the complete life-cycle in the moufl...
946339 - Heterologous radioimmunoassay for bovine follicle-stimulating hormone and its applicati...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-09-19
Journal Detail:
Title:  Psychoneuroendocrinology     Volume:  38     ISSN:  1873-3360     ISO Abbreviation:  Psychoneuroendocrinology     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-15     Completed Date:  2013-10-31     Revised Date:  2014-05-08    
Medline Journal Info:
Nlm Unique ID:  7612148     Medline TA:  Psychoneuroendocrinology     Country:  England    
Other Details:
Languages:  eng     Pagination:  685-93     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adipose Tissue / drug effects,  metabolism
Animals
Atherosclerosis / complications,  drug therapy*,  metabolism,  pathology
Biological Markers / analysis,  metabolism
Blood Glucose / analysis,  metabolism
Disease Models, Animal
Inflammation / complications,  drug therapy*,  metabolism,  pathology
Infusion Pumps
Insulin / blood
Lipids / blood
Male
Oxytocin / administration & dosage,  pharmacology*
Rabbits
Stress, Physiological / drug effects,  genetics
Validation Studies as Topic
Grant Support
ID/Acronym/Agency:
HL-04726/HL/NHLBI NIH HHS; HL-36588/HL/NHLBI NIH HHS; P01 HL036588/HL/NHLBI NIH HHS; T32 HL007426/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Blood Glucose; 0/Insulin; 0/Lipids; 50-56-6/Oxytocin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glucocorticoid excess and the developmental origins of disease: two decades of testing the hypothesi...
Next Document:  Chemical and thermal unfolding of calreticulin.